Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
HKSE:00876's 9-Day RSI is ranked worse than 61.76% of 863
companies
in the Medical Devices & Instruments industry
Industry Median: 47.47
vs HKSE:00876: 51.52
Kaisa Health Group Holdings (HKSE:00876) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Kaisa Health Group Holdings 9-Day RSI Related Terms
HKSE:00876 vs ISRG, BDX, RMD: 9-Day RSI Comparison
For the Medical Instruments & Supplies subindustry, Kaisa Health Group Holdings's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kaisa Health Group Holdings 9-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kaisa Health Group Holdings's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Kaisa Health Group Holdings's 9-Day RSI falls into.
Kaisa Health Group Holdings (HKSE:00876) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kaisa Health Group Holdings (HKSE:00876) has a 9-Day RSI of 51.52 as of Sep. 02, 2026. According to the industry distribution chart, Kaisa Health Group Holdings ranks #533 out of 863 companies in the Medical Devices & Instruments industry, placing it in the top 61.8%.
Is Kaisa Health Group Holdings' 9-Day RSI too high?
Kaisa Health Group Holdings' current 9-Day RSI is 51.52. The Medical Devices & Instruments industry median 9-Day RSI is 47.47. Kaisa Health Group Holdings' value of 51.52 is 8.5% above this industry median. Based on the distribution chart, Kaisa Health Group Holdings ranks #533 out of 863 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Kaisa Health Group Holdings has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kaisa Health Group Holdings' 9-Day RSI compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Kaisa Health Group Holdings ranks #533 out of 863 companies for 9-Day RSI. This places Kaisa Health Group Holdings in the lower half of its industry. The industry median 9-Day RSI is 47.47. Kaisa Health Group Holdings' value of 51.52 is 8.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Medical Devices & Instruments company?
The median 9-Day RSI among Medical Devices & Instruments companies is 47.47, based on 863 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kaisa Health Group Holdings's current 9-Day RSI of 51.52 is 8.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median 9-Day RSI is 47.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kaisa Health Group Holdings's current 9-Day RSI is 51.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaisa Health Group Holdings stock overvalued right now?
Based on GuruFocus' analysis, Kaisa Health Group Holdings (HKSE:00876) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.94, compared to a current price of HK$2.00 — trading 112.8% above its estimated fair value. The current 9-Day RSI is 51.52 and 8.5% above the Medical Devices & Instruments industry median of 47.47. Kaisa Health Group Holdings' overall GF Score™ is 37/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Kaisa Health Group Holdings (HKSE:00876), the current 9-Day RSI is 51.52 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kaisa Health Group Holdings (HKSE:00876) Overvalued in 2026?
Based on GuruFocus' analysis, Kaisa Health Group Holdings stock appears to be overvalued.
The current stock price of HK$2.00 is trading 112.8% above its estimated GF Value™ of HK$0.94.
GuruFocus considers Kaisa Health Group Holdings to be Significantly Overvalued.
Key valuation signals for HKSE:00876:
9-Day RSI: 51.52
GF Value™: HK$0.94 vs. price of HK$2.00 (112.8% above fair value)
Industry Position: 8.5% above the Medical Devices & Instruments median (#533 of 863)
No single metric tells the full story. See the HKSE:00876 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kaisa Health Group Holdings Ltd, through its subsidiaries are mainly engaged in the manufacturing and sale of dental prosthetics and implant instruments, and the provision of sports rehabilitation services. The Group operates in two reportable segments: Dental Business, which consists of manufacturing and trading in dental products; and the Health Care Business, which provides services for sport rehabilitation, including postoperative rehabilitation, sports injury rehabilitation, chronic pain, scoliosis, deformity correction, other rehabilitation services, and health leisure business. The majority of its revenue is generated from the Dental business segment. Geographically, the Group generates maximum revenue from the People's Republic of China, and the rest from other countries.
37GF Score
Get the complete analysis for HKSE:00876
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00876 has been successfully added to your 
